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 There has been remarkable progress made in the diagnosis and treatment of multiple myeloma (MM). The median survival 
of the disease has doubled as a result of several new active drugs. These advances have necessitated a revision of the 
disease definition and staging of MM. Until recently, MM was defined by the presence of end-organ damage, specifically 
hypercalcemia, renal failure, anaemia, and bone lesions (CRAB features) that can be attributed to the clonal process. In 
2014, the International Myeloma Working Group (IMWG) updated the diagnostic criteria for MM to add three specific 
biomarkers that can be used to diagnose the disease in patients who did not have CRAB features: clonal bone marrow 
plasma cells greater than or equal to 60%, serum free light chain (FLC) ratio greater than or equal to 100 provided involved 
FLC level is 100 mg/l or higher, or more than one focal lesion on MRI. In addition, the definition was revised to allow CT 
and PET-CT to diagnose MM bone disease. 
 With the introduction of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs), major improvements have 
been achieved in the treatment and outcome of MM. Different treatment combinations are now in use and newer the-
rapies are being developed. However, nearly all MM patients ultimately relapse, even those who experience a complete 
response to initial therapy. Management of the relapsed disease remains a critical aspect of MM care and an important 
area of ongoing research. The aim of this review is to summarise the current methods of diagnosis and treatment of MM.
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Incidence and epidemiology 
Multiple myeloma (MM) accounts for 1% of all cancers and 10-
15% of all blood cancers. The incidence in Europe is 4.5–6.0/100 
000/year with a median age at diagnosis of 72 years; the mor-
tality is 4.1/100 000/year [1]. Over 90% of MM cases refer to 
patients >50 years old. Only 35% of the patients are younger 
than 65 years at the moment of diagnosis. Individuals under 
40 years of age count for up to 2% of all cases [2]. The annual 
incidence in Poland in 2017 was approximately 8/100 000/year 
[3]. The median overall survival in MM is approximately 6 years 
[4]. In the subset of patients eligible for autologous stem cell 
transplantation (ASCT), 4-year survival rates are more than 80%; 
the median overall survival (OS) among these patients is appro-
ximately 8 years [5]. Among elderly patients (age >75 years), 
median OS is lower, and is approximately 5 years [4]. Particularly 
poor prognosis concerns MM patients with central nervous 
system involvement (median OS: 7 month) [6]. 
Multiple myeloma arises from a terminally differentiated 
postgerminal centre plasma cell. The pathogenesis of MM is 
complex, and many steps in the pathway are not fully eluci-
dated. Most cases of MM are preceded by the premalignant 
asymptomatic states of monoclonal gammopathy of undeter-
mined significance (MGUS) and smouldering MM (SMM) [7]. 
The progression of MGUS to MM is approximately 1% of cases 
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per year, whereas SMM has a much higher rate of progression 
of 10% of cases annually. Approximately 73% of SMM patients 
will progress to MM within 15 years [8]. 
Multiple myeloma is a heterogeneous disease that is based 
on various genetic aberrations. Many of the chromosomal 
abnormalities include translocations in the immunoglobulin-
-heavy chain of chromosome 14, aberrations in chromosomes 
1, 5, 13, and 17, and trisomies [9]. Genetic abnormalities and 
molecular changes are thought to contribute to cell-cycle 
dysregulation and lead to active MM [10].
Diagnosis
In 2014, the International Myeloma Working Group (IMWG) 
revised the diagnostic criteria for MM [10]. The revised dia-
gnostic criteria for MM allow the use of specific biomarkers 
to define the disease in addition to the established CRAB 
(hyperCalcaemia, Renal failure, Anaemia, or lytic Bone lesions) 
features. They also allow the use of modern imaging tools to 
diagnose MM bone disease and clarify several other diagnostic 
requirements. 
The diagnosis of MM requires the presence of one or more 
MM defining events in addition to evidence of either 10% or 
more clonal plasma cells (PC) in bone marrow (BM) exami-
nation or a biopsy-proven plasmacytoma. Multiple myeloma 
defining events consists of established CRAB features as well 
as three specific biomarkers: clonal PC in BM ≥60%, serum 
free light chain (sFLC) ratio ≥100 (provided involved FLC level 
is ≥100 mg/l), and more than one focal lesion on magnetic 
resonance imaging (MRI). Diagnosis of MM should be based 
on the following tests [11, 12]: 
1. Detection and evaluation of the monoclonal (M) com-
ponent by serum and/or urine protein electrophoresis 
(concentrate of 24 hours urine collection); nephelometric 
quantification of IgG, IgA and IgM immunoglobulins; cha-
racterisation of the heavy and light chains by immunofi-
xation; and serum FLC measurement.
2. Evaluation of BM, PC infiltration: BM aspiration and/or 
biopsy. Moreover, the BM sample should be used for cy-
togenetic/fluorescent in situ hybridisation (FISH) studies 
on immunologically recognised or sorted PC and also 
has the potential for immunophenotypic and molecular 
investigations.
3. Evaluation of lytic bone lesions: whole-body low-dose 
computed tomography (WBLD-CT) is the new standard 
for the diagnosis of lytic disease. Conventional radiography 
can also be used if WBLD-CT is not available. 18F-fluorode-
oxyglucose positron emission tomography with CT (PET-
-CT) can be performed to evaluate bone lesions, according 
to availability and resources.
4. Complete blood cell count, with differential serum creati-
nine, creatinine clearance and calcium level.
The definition of MGUS has not changed. Patients need to 
have less than 30 g/l serum M-protein, less than 10% clonal PC 
in BM, and no end-organ damage for this diagnosis. Currently 
no data is available to support the treatment of MGUS patients. 
The diagnosis of a MM demands the presence of a serum 
M-protein of ≥30 g/l, and/or ≥10% of clonal PC in BM. Asymp-
tomatic patients without myeloma-defining events have a 
so-called SMM, which may progress to a symptomatic MM over 
time. The presence of end organ damage, primarily the CRAB-
-criteria, define an underlying MM in need of therapy. In the 
most recent update of the criteria for diagnosis of MM, three 
additional myeloma-defining events have been introduced to 
discriminate symptomatic MM without evidence of classical 
end-organ damage from SMM: clonal PC of 60% or greater in 
the bone marrow, a serum FLC ratio of 100 or greater, or more 
than one focal lesion larger than 5 mm on MRI [10]. To address 
these additional MM defining events, the term “SLiM-CRAB” 
(SLiM: S = sixty; Li = light chain; M = MRI) was coined soon 
after publication of the updated criteria. The new definitions 
of MGUS, SMM and symptomatic MM are shown in table I [10]. 
Staging and risk classification
The course of MM is highly variable, and the clinical behaviour 
is remarkably heterogeneous. Many studies have identified 
prognostic factors capable of predicting this heterogeneity in 
survival: serum ß2-microglobulin, albumin, C-reactive protein 
(CRP), and lactate dehydrogenase (LDH). More precise estima-
tion of prognosis requires an assessment of multiple factors. As 
in other cancers, OS in MM is affected by host characteristics, 
tumour burden (stage), biology (cytogenetic abnormalities), 
and response to therapy [13]. 
Tumour burden in MM has traditionally been assessed 
using the Durie-Salmon Staging (DSS). The International Sta-
ging System (ISS) has now replaced the DSS system [14]. The 
R-ISS staging system is a new risk stratification algorithm with 
an improved prognostic power incorporating ISS, chromoso-
mal abnormalities, and LDH levels (tab. II) [15]. 
Some institutions are also incorporating a risk-adapted ap-
proach to treatment decisions. The Mayo Stratification of My-
eloma and Risk-Adapted Therapy (mSMART) classifies risk based 
on cytogenetic abnormalities [16]. Patients with deletions of the 
long arm of chromosome 13 and translocations of chromoso-
mes 4 and 14 are considered to have high-risk disease. Deletion 
of 17p13, which results in mutations in the tumour-suppressor 
protein 53, is also associated with a poorer outcome [16].
Response evaluation
The definition of response established by the IMWG in 2006 
has been updated in 2016 [17]. The IMWG uniform response 
criteria are most often used to assess response to drug the-
rapy. Responses include stringent complete response (sCR), 
complete response (CR), very good partial response (VGPR), 
partial response (PR), and stable disease (SD) [17]. The response 
criteria incorporate the degree of reduction of serum, and urine 
M-protein by electrophoresis and immunofixation, plasmacy-
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tomas, and PC in BM. Standard IMWG uniform response criteria 
for MM are presented in table III [17]. 
The quality and the depth of response have improved over 
the last 5 years in the context of novel agent-based therapies, 
allowing for the introduction of new response grades, namely 
minimal residual disease (MRD) criteria including sequencing 
MRD negativity, flow MRD negativity, imaging plus negativity 
and sustained MRD negativity. There is a statistical relationship 
between the achievement of CR, MRD negativity and progres-
sion free survival (PFS), or OS. 
Treatment overview
The goals of MM treatment have evolved with advances in 
drug therapy, and more sensitive monitoring. The primary 
goal is to achieve a deep, long-lasting response. Additionally, 
therapy should control disease, minimise complications, and 
improve quality of life. Myeloma treatment depends on whe-
ther the patient is symptomatic. Patients with MGUS, and SMM 
are usually observed, and treatment is initiated upon disease 
progression to active MM. There is no evidence that early 
treatment of SMM prolongs OS. Patients with symptomatic 
Table I. Diagnostic criteria for monoclonal gammopathy of undetermined significance, smouldering multiple myeloma, and symptomatic multiple myeloma
Definition of Monoclonal gammopathy of undetermined significance
All tree criteria must be met: 
• serum M-protein (non-IgM type) <30 g/l 
• clonal bone marrow plasma cells <10%*
• absence of end-organ damage such as hyperCalcemia, renal insufficiency, anaemia, and bone lesions (CRAB) that can be attributed to the plasma cell 
proliferative disorder 
Definition of smouldering multiple myeloma
Both criteria must be met: 
• serum M-protein (IgG or IgA) ≥30 g/l, or urinary monoclonal protein ≥500 mg per 24 hours and/or clonal bone marrow plasma cells 10–60% 
• absence of MM defining events or amyloidosis 
Definition of symptomatic multiple myeloma
Both criteria must be met: 
• Clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary plasmacytoma 
• Any one or more of the following MM defining events: 
– Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically: 
· Hypercalcemia: serum Ca >0.25 mmol/l (>1 mg/dl) higher than the upper limit of normal or >2.75 mmol/l (> 11 mg/dl), 
· Renal insufficiency: CrCl <40 ml per minute or serum creatinine >177 μmol/l (>2 mg/dl), 
· Anaemia: Hb value of >2 g/dl below the lower limit of normal, or a Hb value <10 g/dl, 
· Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT 
– Clonal bone marrow plasma cell percentage ≥60%
– Involved: uninvolved serum FLC ratio ≥100 (involved FLC level must be ≥100 mg/l) 
– >1 focal lesions on MRI studies (at least 5 mm in size) 
Ca – calcium; CT – computed tomography; CrCl – creatinine clearance; FLC – free light chain; Hb – hemoglobin; Ig – immunoglobuline; MRI – magnetic resonance imaging; MM – 
multiple myeloma; PET-CT – positron emission tomography-CT
*A bone marrow can be deferred in patients with low risk MGUS (IgG type, M protein <15 g/l, normal free light chain ratio) in whom there are no clinical features concerning for 
myeloma 
Table II. The International staging system (ISS) and revised International staging system (R-ISS) for multiple myeloma
Stage Criteria Frequency (%) Median OS (months)
ISS
I
•  b2-microglobulin <3.5 mg/l, and
• Albumin (serum) >35 g/l
28 62
II • Neither I or III 62 45
III •  b2-microglobulin >5.5 mg/l 10 29
R-ISS
I
•  b2-microglobulin <3.5 mg/l,
• Albumin (serum) >35 g/l, and 
• No high-risk cytogenetics, and
• Normal LDH (defined as less than ULN)
28 82
II • Not R-ISS stage I or III 62 62
III
•  b2-microglobulin >5.5 mg/l regardless of albumin levels (serum), and
• High-risk cytogenetics: del(17p), t (4;14) or t (14;16) or 
• High LDH (defined as higher than ULN)
10 40
ISS – International staging system; LDH – lactate dehydrogenase; OS – overall survival; R-ISS – revised International staging system; ULN – upper limit of normal
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MM require treatment. This treatment is patient-specific and 
depends on numerous factors, including cytogenetics, disease 
stage, age, comorbidities, and performance status. 
Survival in MM has improved significantly in the last 15 year. 
The initial impact came from the introduction of thalidomide, 
bortezomib, and lenalidomide. In the last decade, carfilzomib, 
pomalidomide, panobinostat, ixazomib, elotuzumab, daratu-
mumab, isatuximab, and selinexor have been approved by 
the European Medicines Agency (EMA) for the treatment of 
relapsed MM, and promise to improve outcomes further. 
All patients with a diagnosis of symptomatic MM require 
immediate treatment. Initial choice of therapy is driven by 
whether a patient is eligible for an ASCT, because certain 
agents, such as alkylating agents, should typically be avo-
ided in those who are transplant eligible. Initial therapy for 
patients with MM is also based on genetic risk stratification 
of the disease. Patients with high-risk disease require a CR 
treatment for long-term OS and thus benefit from an aggres-
sive treatment strategy. Standard-risk patients have similar 
OS regardless of whether or not CR is achieved and thus can 
either be treated with an aggressive approach, or a sequential 
therapy approach. 
The clinician must decide whether the patient is eligible 
or not for ASCT. The eligibility criteria vary from country to 
country. In European countries, ASCT is recommended under 
65–70 years of age, but nowadays it depends upon the “phy-
siological age” rather than the chronological age of the patient. 
Furthermore, serum creatinine level, the Eastern Cooperation 
Oncology Group (ECOG) performance status, and the New York 
Heart Association functional status need to be considered. The 
current guidance of European Society for Medical Oncology 
(ESMO) for MM treatment is shown in figure 1 [18].
Initial treatment in patients eligible for autologous stem 
cell transplantation 
The current treatment paradigm for newly diagnosed MM 
patient eligible for ASCT consists of four phases: induction 
remission, transplantation, post-transplant treatment (conso-
lidation, and maintenance therapy).
Induction remission
Induction therapy usually consists of four to six cycles of thera-
py with the aim of achieving rapid disease control, improving 
symptoms and allowing for subsequent stem cell collection. 
Bortezomib with dexamethasone (VD) is the standard back-




Molecular CR CR plus negative ASO-PCR, sensitivity 10-5
Immunophenotypic CR Stringent CR plus absence of phenotypically aberrant PCs (clonal) in BM with a minimum of 1 million total BM cells 
analysed by multiparametric flow cytometry (with >4 colours)
Stringent CR CR as defined below plus normal sFLC ratio and absence of clonal PCs in BM biopsy by immunohistochemistry or 2- to 
4-colour flow cytometry
CR Negative IF on the serum and urine and disappearance of any soft tissue plasmacytomas and <5% PCs in BM
VGPR Serum and urine M-protein detectable by IF but not on electrophoresis or >90% reduction in serum M-protein plus urine 
M-protein level <100 mg per 24 hours
PR • ≥50% reduction of serum M-protein plus reduction in 24-hour urinary M-protein by ≥90% or to <200 mg per 24 hours. 
If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and 
uninvolved FLC levels is required.
• If serum and urine M-protein are unmeasurable, and sFLC assay is also unmeasurable, ≥50% reduction in plasma cells is 
required in place of M-protein, provided baseline bone marrow PCs percentage was ≥30%.
• In addition to these criteria, if present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also 
required 
MR • ≥25% but ≤49% reduction of serum M-protein and reduction in 24-hour urine M-protein by 50–89%. 
• In addition to the above listed criteria, if present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is 
also required 
PD Any one or more of the following criteria: 
• Increase of 25% from lowest confirmed response value in one or more of the following criteria: 
– Serum M-protein (absolute increase must be ≥5 g/l),
– Serum M-protein increase ≥10 g/l, if the lowest M component  was ≥5 g/dl,\
– Urine M-protein (absolute increase must be ≥ 200 mg/24 hours). 
• In patients without measurable serum and urine M-protein levels, the difference between involved and uninvolved sFLC 
levels (absolute increase must be >10 mg/dl).
• In patients without measurable serum and urine M-protein levels and without measurable involved sFLC levels, BM PCs 
percentage irrespective of baseline status (absolute increase must be ≥10%). 
• Appearance of (a) new lesion(s), ≥50% increase from nadir of >1 lesion, or ≥50% increase in the longest diameter of 
a previous lesion >1 cm in short axis, ≥50% increase in circulating PCs (minimum of 200 cells per μl) if this is the only 
measure of disease. 
ASO-PCR – allele-specific oligonucleotide polymerase chain reaction; BM – bone marrow; CR – complete response; IF – immunofixation; M – monoclonal; MR – minimal response; 
PR – partial response; PCs – plasma cells; PD – progression disease; sFLC – serum free light chain; VGPR – very good partial response
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bone of induction therapy [19, 20]. The addition of a third 
agent, thalidomide (VTD) [21], cyclophosphamide (VCD) [22], 
doxorubicine (PAD) [23], or lenalidomide (VRD) [24] provides 
higher response rates. In prospective trials, induction with 
VTD is superior to VCD in terms of response rate, at the cost 
of a higher incidence of peripheral polyneuropathy (PN) but 
lower incidence of haematological toxicities [25]. To reduce 
the PN incidence, the French Intergroupe Francophone du 
Myelome (IFM) proposed the VTD regimen with reduced do-
ses of bortezomib, and thalidomide, which is associated with 
a lower incidence grade ¾ PN (14% vs. 34%), but at the expense 
of lower response rates [26]. Bortezomib, cyclophosphamide, 
and dexamethasone was also shown to be, as effective as PAD 
in terms of response, but less toxic [27]. Replacement of tha-
lidomide by lenalidomide in the VRD regimen induces higher 
CR rates before and after ASCT (47%, and 88% of patients with 
a VGPR or better, respectively) [24]. Current regimens used in 
the front-line are listed in table IV. 
Other highly effective combinations such as carfilzomib, 
lenalidomide, and dexamethasone (KRd), or ixazomib, lenalido-
mide, and dexamethasone (IRd) are currently under evaluation 
in phase III trials. 
However, the introduction of monoclonal antibodies will 
change the landscape of induction therapy in the near fu-
ture. Ongoing prospective trials combining daratumumab 
with VTD (Cassiopeia) or VRD (Perseus), or elotuzumab with 
VRD are exploring the role of induction with antibody-based 
quadruplets. 
ASCT eligibility decided by age and fitness
Treatment selection guided by age, PS, comorbidities, previous treatment (type, efficacy, tolerance),  
number of prior lines, available treatment options, type of relapse
Relapsed/refractory
At 2nd or subsequent relapse
Pd (backbone) + Cyclo, Ixa, V,  
Dara, Elo.
Clinical trial
Dara (single agent  
or combination)
ASCT eligible








1st relapse after IMiD-based induction
Doublets Kd/Vd Rd
Triplets based on V 
DVd, PanoVd,
EVd, VCD
Triplets based on Rd: 
DRd, ERd, KRd, IRd
Not recommended
Not recommended
1st relapse after V-based induction
ASCT ineligible
First option: VMP or Rd or VRd
Second option: MPT or VCD
Other options: CTD, MP, BP
Figure 1. European Society for Medical Oncology guidance for multiple myeloma treatment; ASCT – autologous stem cell transplantation; BP 
– bendamustine, prednisone; Cyclo – cyclophosphamide; CTD – cyclophosphamide, thalidomide, dexamethasone; Dara – daratumumab; DVd – 
daratumumab, bortezomib, dexamethasone; Elo – elotuzumab; ERd – elotuzumab, lenalidomide, dexamethasone; EVd – elotuzumab, bortezomib, 
dexamethasone; Ixa – ixazomib; IRd – ixazomib, lenalidomide, dexamethasone; IMiD – immunomodulathory drug; Kd – karfilzomib, dexamethasone; 
MP – melphalan, prednisone; MPT – melphalan, prednisone, thalidomide; PAD – bortezomib, doxorubicin, dexamethasone; PanoVd – panobinostat, 
bortezomib, dexamethasone; Pd – pomalidomide, dexamethasone; PS – personal status; Rd – lenalidomide, low-dose dexamethasone; RVD – 
lenalidomide, bortezomib, dexamethasone; V – bortezomib; VCD – bortezomib, cyclophosphamide, dexamethasone; Vd – bortezomib, dexamethasone; 
VMP – bortezomib, melphalan, prednisone; VRd – bortezomib, lenalidomide, low-dose dexamethasone; VTD – bortezomib, thalidomide, dexamethasone 
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Stem cell collection 
Peripheral blood progenitor cells are usually collected for more 
than one ASCT (at least 2.5 x 106 CD34 + cells/kg per trans-
plantation). Since the use of lenalidomide can impair stem cell 
collection, apheresis in this situation should be performed after 
3–4 cycles, and may require the use of cyclophosphamide or 
plerixafor.
High dose melphalan (HDM) and ASCT
High-dose melphalan (melphalan 200 mg/m2, MEL200) remains 
the standard conditioning regimen prior to ASCT. A dose reduc-
tion (100–140 mg/m2) is recommended in case of renal impa-
irment (estimated GFR <60 ml/min). In this group of patients, 
including those requiring dialysis, ASCT is feasible but exposes 
the patient to severe mucositis, prolonged hospitalisation and 
an increased risk of transplant-related mortality (4% vs. <1%) [28]. 
Post-transplant treatment 
The concept of consolidation and/or maintenance is a com-
monly adopted approach after transplantation. Consolidation 
after ASCT is a short-term intensive therapy aimed at improving 
the quality of response after transplant. Maintenance consists 
of the administration of a therapy for a prolonged period 
in order to maintain the response achieved after ASCT and 
prevent progression. 
Consolidation with second ASCT
Before the era of novel agents, the main approach was to pro-
pose a second ASCT. However, tandem ASCT did not provide 
any OS, or PFS advantage, except in patients not achieving 
VGPR after the first transplant. [29, 30]. Currently, tandem ASCT 
with HDM as conditioning is recommended for transplant-eli-
gible patients with high-risk cytogenetic features at diagnosis.
Consolidation with new drugs
Initially, bortezomib or VT(D) consolidation were shown to 
increase the quality of response by 30% and were considered 
at least in patients who failed to achieve a VGPR or CR/near 
CR (nCR) after ASCT [31] Nowadays, the role of consolidation 
remains unclear. Trials using either carfilzomib or ixazomib 
in this setting are currently ongoing. Overall, consolidation 
remains a reasonable practice in patients who failed to achieve 
a VGPR or nCR/CR after transplantation.
Maintenance therapy
In young patients following ASCT, phase III randomised trials 
have demonstrated that maintenance therapy with immu-
nomodulatory drugs (IMiDs), either thalidomide or lenalido-
mide, prolongs PFS [19]. A meta-analysis demonstrated that 
lenalidomide maintenance following ASCT is associated with 
an overall OS benefit of more than two years [32]. Bortezomib 
maintenance was also evaluated during a two-year study and 
was associated with a survival benefit over thalidomide main-
tenance, but induction was not identical in the two arms of this 
prospective trial [23]. Currently, bortezomib and thalidomide 
are not approved in this setting.
In elderly patients following induction, several randomi-
sed trials have explored the benefit of maintenance therapy 
in terms of OS using either IMiDs or bortezomib: melphalan 
with prednisone (MP) or a reduced-dose regimen of cyc-
lophosphamide, thalidomide, and dexamethasone (CTD) 
with or without thalidomide maintenance [33], MP versus 
melphalan, prednisone, lenalidomide (MPR) versus melpha-
lan, prednisone, lenalidomide and followed by maintenan-
ce with lenalidomide (MPR-R) [34], bortezomib, melphalan, 
prednisone, thalidomide followed by maintenance with bor-
tezomib, and thalidomide (VMPT-VT) versus bortezomib, 
melphalan, prednisone (VMP) [35], VMP versus bortezomib, 
thalidomide, prednisone (VTP) followed by either bortezo-
mib, and prednisone (VP) or VT maintenance [36] systematic 
maintenance therapy currently can not be recommended in 
elderly patients. 
Initial treatment in patients not eligible for ASCT 
For patients with newly-diagnosed (ND) MM who are ineligible 
for ASCT due to age or other comorbidities, chemotherapy is 
the only option. Many patients will benefit not only in survival, 
but also in quality of life. Immunomodulatory agents, such as 
lenalidomide and thalidomide, and proteasome inhibitors (PIs), 
such as bortezomib, are highly effective and well tolerated. 
There has been a general shift to using these agents upfront 
in transplant-ineligible patients.
All the previously mentioned regimens can also be used 
in transplant-ineligible patients. Although no longer the pre-
ferred treatment, melphalan can be considered in resource-
-poor settings [37]. Patients who are not transplant-eligible 
are treated for a fixed period of 9 to 18 months, although 
lenalidomide, and dexamethasone (Rd) is often continued 
until relapse [38, 39].
The two following options are recommended based on 
data from randomised phase III trials: VMP (bortezomib ad-
ministered subcutaneously) [39] or Rd [40]; both VMP and 
Rd are approved in this setting by the European Medicines 
Agency (EMA). Melphalan, prednisone, thalidomide (MPT) is 
also approved by the EMA, but is inferior to Rd in terms of PFS 
and OS [40, 41]. The regimen has a high toxicity rate (>50%) 
and a deep vein thrombosis rate of 20%, so patients undergo-
ing treatment with this regimen require thromboprophylaxis. 
Bortezomib, cyclophosphamide with dexamethasone induces 
high response rates and prolonged PFS [19]. Lenalidomide with 
dexamethasone has recently been compared prospectively 
with Rd with bortezomib (VRd), and the addition of bortezo-
mib resulted in significantly improved PFS and OS and had an 
acceptable risk-benefit profile [42]. Bendamustine, and pred-
nisone (BP) is also approved by the EMA in patients who have 
clinical neuropathy at time of diagnosis, precluding the use 
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of thalidomide according to the MPT regimen or bortezomib 
according to the VMP regimen [43]. Melphalan, prednisone, 
and lenalidomide is not routinely used and cannot be consi-
dered as a standard of care. Cyclophosphamide, thalidomide, 
and dexamethasone has also been compared with MP and 
is superior in terms of response rates, but does not induce 
a clear survival advantage over MP. Current regimens used in 
front-line are listed in table IV.
Treatment of relapsed/refractory multiple 
myeloma
Table V shows definitions of relapsed and refractory (RR) MM 
[44]. In the relapsed setting, optimal management of MM 
is complex and ESMO guidelines indicate that the selec-
tion of therapy should be guided by a number of different 
parameters including: patient age; performance status; co-
morbidities; the type, efficacy and tolerance of the previous 
treatment; the number of prior treatment lines; the available 
remaining treatment options; the interval since the last the-
rapy; and the type of relapse [18]. Relapses in MM may be 
clinical or biochemical, and in the case of biochemical relapse, 
salvage treatment can be delayed. For the youngest, fittest 
patients who have initially benefited from their first ASCT, 
a second ASCT may be considered, although, this option is 
still infrequently used [18, 45]. 
For most patients, the treatment approach will need to 
be based on prior exposure and toxicity. Wherever prior tre-
atment was IMiD-based, current guidelines advise a switch to 
a proteasome inhibitor (PI) doublet (bortezomib or carfilzomib 
with dexamethasone) or bortezomib-based triplet therapy 
with dexamethasone and either daratumumab, panobinostat, 
elotuzumab or cyclophosphamide (fig. 1) [18]. 
In first relapse after bortezomib-based induction, treat-
ment should be changed to an IMiD-based treatment regimen 
with or without a novel agent. Other options include doublet 
Rd therapy or triplets on an Rd backbone – for example, with 
the addition of daratumumab, carfilzomib, ixazomib or elotu-
zumab (fig. 1) [18].
If both IMiD’s and PI’s have been exhausted and the patient 
is experiencing a second or subsequent relapse, current ESMO 
guidelines recommend the alternative option of a clinical trial 
or daratumumab monotherapy if this has not been previously 
Table V. Definitions of relapsed and refractory multiple myeloma 
Multiple myeloma Definition
Primary refractory Non-responsive disease, in which MR or better has never been achieved, with no significant change in M-protein 
level, and no evidence of clinical progression 
Refractory Non-responsive disease, while on primary or salvage therapy, or progressing within 60 days of last therapy 
Relapsed Previously responding disease that progresses and requires initiation of salvage therapy, but does not meet criteria 
for either primary refractory disease or relapsed and refractory disease 
Relapsed and refractory Non responsive disease, while on salvage therapy or progressing within 60 days of last therapy, in patients who have 
achieved at least MR at some point previously before, then progressing in their course 
Double refractory Disease refractory to both PIs and IMiDs 
IMiDs – immunomodulatory inhibitors; MR – minimal response; PI – proteasome inhibitors
Table IV. Currently used first-line regimens in eligible- and ineligible-transplant newly diagnosed multiple myeloma patients
Regimen ORR (%) >VGPR (%) Median PFS (months) 3-years OS rate (%)
Transplant-eligible
VTD [21] 93 63 NR 90
VCD [22] 88 71 NA NA
PAD [23] 90 42 35 61
VRD [24] CR: 49 50 81% at 4 years
Transplant-ineligible
MPT [40] 62 28 21.2 51% at 4 years
VMP [39] 71 CR: 30 22 41
Once-weekly VMP [46] 85 55 33.1 88
VCD [22] 88 71 NA NA
Rd [38] (continuous) 75 44 25.5 59% at 4 years
VRd [42] 81.5 27.8 43 median OS: 75 months
CR – complete response; MPT – melphalan, prednisone, thalidomide; NA – not available; NR – not reached; ORR – overall response rate; OS – overall survival; PAD – bortezomib, 
doxorubicin, dexamethasone; PFS – progression free survival; Rd – lenalidomide, low-des dexamethasone; VCD – bortezomib, cyclophosphamide, dexamethasone; VGPR – very 
good partial response; VMP – bortezomib, melphalan, prednisone; VRd – bortezomib, lenalidomide, low-dose dexamethasone; VRD – bortezomib, lenalidomide, dexamethasone; 
VTD – bortezomib, thalidomide, dexamethasone 
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tried, while combinations based on a pomalidomide backbone 
with ixazomib, cyclophosphamide, bortezomib, daratumumab 
or elotuzumab should also be evaluated (fig. 1) [18]. 
Compelling data from randomised, controlled phase 
III trials support the ability of novel agent-based triplets to 
achieve both superior response rates and prolonged dise-
ase control versus doublet combinations. In several phase 
III studies Rd with ixazomib, carfilzomib, elotuzumab and 
daratumumab versus Rd alone in patients with RRMM have 
demonstrated statistically significant improvement in the 
primary clinical endpoint of PFS when combined with Rd 
versus Rd alone in patients with RRMM. Table VI shows the 
results of selected phase III clinical trials assessing IMiD-ba-
sed (lenalidomide, pomalidomide) chemotherapy in RRMM. 
Significant improvements in PFS were also obtained with 
daratumumab or panobinostat when added to a Vd back-
bone compared to Vd in the relapsed/refractory setting in 
phase III studies. However, the clinical benefit of triplets may 
Table VI. Results of selected phase III clinical trials assessing IMiD-based (lenalidomide, pomalidomide) chemotherapy in relapsed/refractory multiple myeloma
Trial Regimen ORR (%) >CR (%) Median PFS (months) Median OS (months)
Lenalidomide-based

















2-years: 73% vs. 65%
p = 0.04
HR = 0.79





























MM-003 [53] Pd vs. Dex 32 vs. 11 
p < 0.001
7 vs. 1 4.0 vs. 1.9
p < 0.001
HR = 0.5
13.1 vs. 8.1 
p = 0.009
HR = 0.72








ELOQUENT-3 [55] EPd vs. Pd 53 vs. 26 20 vs. 9 10.3 vs. 4.7




CR – complete response; DRd – daratumumab, lenalidomide, dexamethasone; Dex – dexamethasone; EPd – elotuzumab, pomalidomide, dexamethasone; ERd – elotuzumab, 
lenalidomide, dexamethasone; HR – hazard ratio; IRd – ixazomib, lenalidomide, dexamethasone; IMiD – immunomodulathory drug; KRd – karfilzomib, lenalidomide, 
dexamethasone; NR – not reached; ORR – overall response rate; OS – overall survival; Pd – pomalidomide, dexamethasone; PFS – progression free survival; Rd – lenalidomide, 
dexamethasone; Vd – bortezomib, dexamethasone; VPd – bortezomib, pomalidomide, dexamethasone; 
Table VII. Results of selected phase III clinical trials assessing inhibitor proteasoms-based chemotherapy in relapsed/refractory multiple myeloma
Trial Regimen ORR (%) >CR (%) Median PFS (months) Median OS (months)







12 months: 80% vs. 66% 
p = 0.001
HR = 0.57


















Panorama-1 [60] PanoVd vs. d 61 vs. 57
p = 0.009






Dex – dexamethasone; DVd – daratumumad, bortezomib, dexamethasone; HR – hazard ratio; Kd – karfilzomib, dexamethasone; ORR – overall response rate; OS – overall survival; 
PanoVd – panobinostat, bortezomib, dexamethasone; PFS – progression free survival; V – bortezomib; Vd – bortezomib, dexamethasone 
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be less evident in elderly or frail patients. The older or more 
unfit patients with poor performance status may benefit from 
less-intensive triplet regimens or dose reductions. Table VII 
shows the results of selected phase III clinical trials assessing 
IP-based chemotherapy in RRMM.
Treatment of patients with RRMM in Poland using new 
drugs (lenalidomide, pomalidomide, daratumumab, carfilzo-
mib) is carried out in accordance with the Ministry of Health’s 
drug programme “Treatment of patients with refractory or 
recurrent myeloma” which is available at the internet address 
www.gov.pl/web/zdrowie/zdrowie-onkologiczne [61].
Supportive care 
Patients with RRMM are more at risk of frequent infections, 
bone disease or anaemia.
Infections with encapsulated germs should be managed 
proactively, and patients should be vaccinated against influ-
enza, haemophilus influenza and pneumococcus. Intravenous 
bisphosphonates should be started or restarted at relapse, in 
combination with calcium and vitamin D supplementation. 
Local radiation therapy (20–40 Gy) may be required for local 
bone lesions in case of pain or imminent fracture. Anaemia 
should be treated with EPO (erythropoietin 40.000 UI per week, 
or darbepoetin 500 μg per three weeks) or transfusion [62]. 
Prevention of PN and thrombosis should follow the published 
guidelines [63]. 
Conclusions 
Multiple myeloma can present a difficult diagnostic issue, as 
there are a wide variety of presenting symptoms. MM should 
be suspected in patients presenting signs of back pain com-
bined with other systemic symptoms such as fatigue and 
weight loss, or back pain combined with abnormal blood 
tests. Confirmation of a MGUS and an increased (>10%) BM 
plasmacytosis are key determinants for the final diagnosis of 
MM. Despite significant advances in the management of MM, 
the disease remains incurable. Virtually all patients will develop 
relapsed disease, although strides in the field have provided 
opportunities for longer-term remissions.
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